首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1374780

全球腦脊髓液管理市場 -2023-2030

Global Cerebrospinal Fluid Management Market -2023-2030

出版日期: 2023年11月01日 | 出版商:

DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

多年來，全球腦脊髓液管理市場經歷了顯著的成長和變革，影響其動態的因素有很多。中樞神經系統的穩態主要由腦脊髓液 (CSF) 維持。腦脊髓液 (CSF) 的管理需要使用分流器或外部引流系統等工具來維持腦脊髓液流動。

政府新產品的推出和研究，特別是在發展中經濟體，將繼續推動先進腦脊髓液（CSF）分流器或外部引流系統的利用，並推動全球腦脊髓液管理市場。各自的創新產品可用於不同年齡層的人。

市場動態：促進因素與限制因素

不斷成長的合作和收購

在高投資、收入水準和基礎設施發展的推動下，已開發經濟體的醫療保健產業不斷改善。由於研究的不斷增加，一些國家對腦脊髓液管理產生了巨大的需求。不同國家之間的各種合作、收購和技術進步的產品發布將是推動市場成長的關鍵因素。

2023 年 6 月 27 日，著名醫療器材公司和神經外科極其專業的設備或耗材製造商 Spiegelberg GmbH & Co. KG (Spiegelberg) 被瑞士醫療保健公司 Luciole Medical AG 收購。來自 SHS Capital 的大腦監測。收購後，兩家公司將合併其產品線、生產能力和分銷網路，以最大限度地發揮各自的優勢，目標是成為尖端下一代腦監測設備開發的領導者。

此外，2023 年 6 月 26 日，LianMedical（一家專注於加速將突破性醫療技術引入亞洲市場的醫療器材製造商）和 CereVasc, Inc.（一家臨床階段的醫療器材公司，開發神經系統新療法）疾病，聯手將CereVasc 的eShunt 系統及相關產品帶給中國、台灣、香港和澳門的消費者和醫療保健專業人員。

此外，擴大利用新技術和不同類型的腦脊髓液管理系統來進行治療或多種研究目的。腦液漏的增加和創新管理產品開發研究的增加將是推動腦脊髓液管理市場成長的主要因素。

與分流術相關的併發症

儘管外科手術和抗生素預防有所改進，但感染仍然是分流術最嚴重的副作用。因此，用於分流器和 EVD 的抗菌生物材料已經誕生。了解這些問題的外科、生物材料和微生物成分對於此類設備的實驗室評估是必要的。

最常見的是，一些與皮膚菌叢相關的低毒力微生物是腦脊髓液分流感染的原因。在大約 50% 至 80% 的分流感染中，凝固酶陰性和凝固酶陽性葡萄球菌被證明是常見的病原體。

The global cerebrospinal fluid management market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The central nervous system's homeostasis is crucially maintained by cerebrospinal fluid (CSF). The management of cerebral spinal fluid (CSF) entails the use of tools like shunts or external drainage systems to keep the CSF flowing.

Government novel product launch and research, particularly in developing economies, will continue to drive utilization of advanced cerebrospinal fluid (CSF) shunt or external drainage systems and boost the global cerebrospinal fluid management market. The respective innovative products are may be utilized in people with different age groups.

Market Dynamics: Drivers & Restraints

Growing collaborations and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for cerebrospinal fluid management owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On June 27, 2023, the Spiegelberg GmbH & Co. KG (Spiegelberg), a well-known medical device firm and manufacturer of extremely specialized devices or consumables for neurosurgery, was bought by Luciole Medical AG, a Swiss health care company with a focus on brain monitoring, from SHS Capital. After the acquisition, the businesses will merge their product lines, production capabilities, and distribution networks to maximize their strengths with the goal of emerging as a leader in the development of cutting-edge next-generation brain monitoring devices.

Additionally, on June 26, 2023, LianMedical, a manufacturer of medical devices focused on speeding up the introduction of ground-breaking medical technologies to markets in Asia, and CereVasc, Inc., a clinical-stage medical device business developing new therapies for neurological diseases, joined forces to bring CereVasc's eShunt System along with associated products to consumers and healthcare professionals in China, Taiwan, Hong Kong, and Macau.

Furthermore, the rising utilization of novel technology and different types of cerebrospinal fluid management systems for the treatment or several research purposes. Rising cerebral fluid leak and increasing research for innovative management product development will be a major factor driving the growth of the cerebrospinal fluid management market.

Complications associated with the shunts

Despite improvements in surgical procedures and antibiotic prophylaxis, infection is still the most severe side effect of shunts. As a result, antimicrobial biomaterials for shunts and EVDs have been created. Understanding the surgical, biomaterials, and microbiological components of the issues is necessary for the laboratory assessment of such devices.

Most frequently, some skin flora-associated low-virulence organisms are responsible for CSF shunt infections. In approximately 50% to 80% of the shunt infections, coagulase-negative and coagulase-positive staphylococci were shown to be the common causative agents.

Segment Analysis

The global cerebrospinal fluid management market is segmented based on product type, age group, end user and region.

Cerebrospinal Fluid (CSF) Shunt segment accounted for approximately 56% of market share

Shunts of cerebrospinal fluid are employed to treat hydrocephalus, which is brought on by increased pressure inside the brain. They are meant to be permanent fixtures. External ventricular drainage (EVD), which is utilized for sudden increases in pressure such those brought on by trauma or hemorrhage, is a more transient solution. Patients have CSF shunts implanted to drain fluid from their cysts, ventricles, and subdural deposits to organs that can absorb it, including the peritoneum or atrium.

The most frequent neurosurgical procedure carried out in the US is the insertion of CSF shunts. For existing or probable hydrocephalus/fluid space collections caused by spina bifida or intraventricular hemorrhage, shunts are most frequently implanted in young patients, and they have reduced mortality from these disorders.

On February 10, 2021, the first patient in a study of CereVasc, Inc.'s eShunt System, an investigational device aimed at treating communicating hydrocephalus (CH), which is among the most prevalent neurological conditions in the world, has been treated. CereVasc, Inc. is a clinical-stage medical equipment company creating novel, minimally invasive therapies for neurological diseases. The eShunt device, the first modern minimally invasive procedure for CH, has the potential to provide considerable advantages over the standard of care, a 50-year-old neurosurgical operation marked by frequent failure, an increased risk of infection, and high costs.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for cerebrospinal fluid management in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for cerebrospinal fluid management.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of products, and increase in biopharmaceutical or medical device business establishment across the region are also contributing to the growth of cerebrospinal fluid management market share of this region. The market in this area is growing as people become more aware of various novel innovative products such as cerebrospinal fluid (csf) shunt. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global cerebrospinal fluid management market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for cerebrospinal fluid management in the U.S. United States have been proactive in executing several initiatives or researches, stimulating cerebrospinal fluid management demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global cerebrospinal fluid management market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for cerebrospinal fluid management. Now several research studies have been initiated and companies have again started launching novel products with high efficiency. Overall, the impact of the pandemic on the global cerebrospinal fluid management market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for innovative products, like external drainage system.

Key Developments

On July 6, 2023, the External Ventricular Drain (EVD) catheter set, Codman Bactiseal is used to treat patients who have hydrocephalus as a side effect of aneurysmal subarachnoid hemorrhage (aSAH), according to positive clinical and financial results stated by Integra LifeSciences Holdings Corporation, an established global medical technology company.
On April 8, 2022, the VentrEX Complete is the ideal option for lumbar or ventricular drainage because it includes the VentrEX EVD System with a disposable stand. Its extensive range of intelligent functions, properly labeled parts, and easy-to-read scale ensure simple handling with the highest level of safety.

Competitive Landscape

The major global players in the market include: Medtronic, Integra LifeSciences, DePuy Synthes (Johnson & Johnson MedTech), B. Braun SE, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Neuromedex GmbH, MOLLER Medical GmbH, Argi Grup and Wellong Instruments Co., Ltd.

Why Purchase the Report?

To visualize the global cerebrospinal fluid management market segmentation based on product type, age group, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of cerebrospinal fluid management market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global cerebrospinal fluid management market report would provide approximately 61 tables, 56 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Age Group
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing collaborations and acquisitions
  - 4.1.1.2. Rising technological advancements and developments
- 4.1.2. Restraints
  - 4.1.2.1. Complications associated with the shunts
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Cerebrospinal Fluid (CSF) Shunt*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Ventriculoperitoneal (VP) Shunt
- 7.2.4. Ventriculopleural (VPL) Shunt
- 7.2.5. Ventriculoatrial (VA) Shunt
7.3. External Drainage System
- 7.3.1. External Ventricular Drainage (EVD)
- 7.3.2. Lumbar Drainage
- 7.3.3. Cisternal Drainage

8. By Age Group

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 8.1.2. Market Attractiveness Index, By Age Group
8.2. Pediatric *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adult
8.4. Geriatric

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Geriatric

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Medtronic*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Integra LifeSciences
12.3. DePuy Synthes (Johnson & Johnson MedTech)
12.4. B. Braun SE
12.5. Natus Medical Incorporated
12.6. Spiegelberg GmbH & Co. KG
12.7. Neuromedex GmbH
12.8. MOLLER Medical GmbH
12.9. Argi Grup
12.10. Wellong Instruments Co., Ltd.

LIST NOT EXHAUSTIVE